MYCN is aberrantly overexpressed in PTCL. (A) Normalized counts for MYCN in the Leuven PTCL cohort of 28 cases. (B) Normalized counts for MYCN in three published data sets (RNA-seq24 and microarray22,23). AITL, angioimmunoblastic T-cell lymphoma. (C) Heat map showing expression of MYC target genes from the hallmark gene sets in PTCL cases from the Leuven and Kyoto cohorts. Samples indicated in green harbor overexpression of MYCN. (D) Gene set enrichment analysis (GSEA) showing enrichment of different MYC target gene sets in the differentially expressed genes of PTCL with a high MYC signature compared with PTCL with a low MYC signature. NES, normalized enrichment score. (E) Normalized enrichment scores for different hallmark gene sets in MYC high vs low PTCL. (F) GSEA showing enrichment of an embryonic stem-cell-like signature as described by Wong et al.25 (G) Lugano staging for the patients with PTCL in the Leuven cohort. (H) Pie chart representing the sex of the patients with PTCL in the MYC low (left) and MYC high (right) subgroups. The difference between the female presence in the 2 groups was calculated using a hypergeometrical distribution (P = .016). See also supplemental Figure 1.
